The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The writing committee says collaborative efforts and patient-level perspective can improve management of pain in this ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Grant ...